Manejo de la Osteoartritis
[Management of osteoarthritis]Generoso Guerra1
1. Consultorios Royal Center, Panamá, Rep de Panamá;
Descargas
Archivos adicionales
Resumen
De todas las enfermedades del sistema musculoesquelético, la osteoartritis (OA) es la más frecuente de las artritis, lo que conlleva a enormes gastos para la sociedad y una gran morbilidad para las personas que la padecen. Se caracteriza por afectar toda la articulación, incluyendo la degradación del cartílago, el remodelamiento óseo, la formación de osteofitos y la inflamación de la membrana sinovial. En consecuencia, se produce dolor, rigidez, hinchazón y pérdida de la función articular con marcada limitación funcional. El manejo de esta entidad implica una terapia no farmacológica, el uso de drogas para el alivio del dolor y cirugía cuando las medidas anteriores han fallado. Dentro de las medidas no farmacológicas destacan la educación, los ejercicios para el fortalecimiento muscular, la terapia física, la disminución de peso y las ortesis o dispositivos para asistir en la deambulación. En cuanto a las drogas recomendadas podemos mencionar a los antiinflamatorios no esteroideos tanto tópicos como orales y los glucocorticoides intraarticulares. Finalmente, la meniscectomía parcial por artroscopía solo se ha recomendado cuando existe bloqueo en la rodilla. En aquellos individuos que sufran de un dolor insoportable o una limitación funcional severa por una enfermedad avanzada debe considerarse el reemplazo total de la articulación.
Abstract
Of all the diseases of the musculoskeletal system, osteoarthritis (OA) is the most common arthritis, leading to enormous costs to society and great morbidity for sufferers. It is characterized by involvement of the entire joint, including cartilage degradation, bone remodeling, osteophyte formation and inflammation of the synovial membrane. This results in pain, stiffness, swelling and loss of joint function with marked functional limitation. Management of this entity involves non-pharmacological therapy, the use of drugs for pain relief and surgery when previous measures have failed. Non-pharmacological measures include education, muscle strengthening exercises, physical therapy, weight reduction and orthoses or devices to assist ambulation. As for recommended drugs, non-steroidal anti-inflammatory drugs, both topical and oral, and intra-articular glucocorticoids are recommended. Finally, partial meniscectomy by arthroscopy has only been recommended when there is knee locking. In individuals suffering from excruciating pain or severe functional limitation due to advanced disease, total joint replacement should be considered.
Citas
[1] Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54:226-229.
[2] https://doi.org/10.1002/art.21562
[3] Neogi T, Felson D, Niu J, et al. Association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ. 2009;339:b2844.
[4] https://doi.org/10.1136/bmj.b2844
[5] NeogiT. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage. 2013;21:1145-1153.
[6] https://doi.org/10.1016/j.joca.2013.03.018
[7] Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Rheumatol. 2020;72(2):220-233.URL: https://doi.org/10.1002/art.41142
[8] Dadabo J, Fram J, Jayabalan P. Noninterventional therapies for the management of knee osteoarthritis. The Journal of knee surgery. 2018;32(01):046-054.URL: https://doi.org/10.1055/s-0038-1676107
[9] Dunlop DD, Song J, Semanik PA, et al. Objective physical activity measurement in the Osteoarthritis Initiative: are guidelines being met? Arthritis Rheum. 2011; 63:3372-82. URL: https://doi.org/10.1002/art.30562
[10] Dunlop DD, Song J, Hootman JM, et al. One hour a week: moving to prevent disability in adults with lower extremity joint symptoms. Am J Prev Med. 2019;56:664-72. URL: https://doi.org/10.1016/j.amepre.2018.12.017
[11] Lo HG, Richard MJ, McAlindon TE, et al. Strength training associates with less knee osteoarthritis: data from the osteoarthritis initiative. Arthritis Rheumatol. 2023 Oct. 23. doi:10.1002/art.42732. Epub ahead of print. URL: https://doi.org/10.1002/art.42732
[12] Raud B, Gay C, Guiget-Auclair C, et al. Level of obesity id directly associated with the clinical and functional consequences of knee osteoarthritis. Sci Rep. 2020;10:3601. URL: https://doi.org/10.1038/s41598-020-60587-1
[13] Shumnalieva R, Kotov G, Monov S. Obesity-related knee osteoarthritis-current concepts. Life. 2023;13:1650. URL: https://doi.org/10.3390/life13081650
[14] Kücükdeveci AA. Rehabilitation interventions in osteoarthritis. Best Pract Res Clin Rheumatol. 202 Jul 4:101846. doi:10.1016/j.berh.2023.101846. Epub ahead of print. URL: https://doi.org/10.1016/j.berh.2023.101846
[15] Bruyère O, Honvo G, Veronese N, et al. An update algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337-350.
[16] https://doi.org/10.1016/j.semarthrit.2019.04.008
[17] Overton C, Nelson AE, Neogi T. Osteoarthritis treatment guidelines from six professional societies: similarities and differences. Rheum Dis Clin North Am. 2022;48:637-657. URL: https://doi.org/10.1016/j.rdc.2022.03.009
[18] Mintarjo JA, Poerwanto E, Tedyanto EH. Current non-surgical management of knee osteoarthritis. Cureus. 2023 Jun 26:15(6):e40966. URL:https://doi.org/10.7759/cureus.40966
[19] Persson MSM, Stocks J, Walsh DA, et al. The relative efficacy of topical non-steroidal anti-inflammatory drugs and capsaicin in osteoarthritis: a network meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2018;26:1575-1582. URL: https://doi.org/10.1016/j.joca.2018.08.008
[20] Sabha M, Hochberg MC. Non-surgical management of hip and knee osteoarthritis; comparison of ACR/AF and OARSI 2019 and VA/DoD 2020 guidelines. Osteoarthr Cartil Open. 2021 Dec. 25;4(1):100232. URL: https://doi.org/10.1016/j.ocarto.2021.100232
[21] Toupin April, Bisaillon J, Welch V, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2019 May,5(5):CD005522. URL: https://doi.org/10.1002/14651858.CD005522.pub3
[22] Lenhard NK, Sullivan JK, Ross EL, et al. Does screening for depressive symptoms help optimize duloxetine use in knee osteoarthritis patients with moderate pain? A cost-effectiveness analysis. Arthritis Care Res. 2022;74:776-789. URL: https://doi.org/10.1002/acr.24519
[23] Katz JN, Aran KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis. A review. JAMA. 2021;325(6):568-578. URL: https://doi.org/10.1001/jama.2020.22171
[24] Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. doi:10.1016/j.bcp.2020.114147. Epub 2020 Jul 10. URL: https://doi.org/10.1016/j.bcp.2020.114147
[25] Sharma L. Osteoarthritis of the knee. N Engl J Med. 2021;384:51-59. URL: https://doi.org/10.1056/NEJMcp1903768
[26] Block JA, Cherny D. Management of knee osteoarthritis. Rheum Dis Clin N Am 2022;48:549-567. URL: https://doi.org/10.1016/j.rdc.2022.02.011
[27] McAlindon TE, Mobasheri A, Reginster JY. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI guidelines. Nat Rev Rheumatol. 2021;17:59-66.URL: https://doi.org/10.1038/s41584-020-00523-9
[28] Abramoff B, Caldera FE. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104:293-311. URL: https://doi.org/10.1016/j.mcna.2019.10.007
Licencia
Derechos de autor 2023 Infomedic Intl.Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.